solid tumors

We believe it may be very symbolic for Pliant´s data readout. Bloomberg Wealth with David Rubenstein Renowned financier, Co-Founder of The Carlyle Group, and philanthropist David Rubenstein provides unparalleled access to the world’s most successful investors. In one-on-one interviews, Rubenstein will learn investing strategies and tactics from some of the world’s top wealth creators. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.

As mentioned above, Pliant´s trading at 12 times higher valuation vs a drug with much stronger results does not make sense. At 36 weeks of treatment with C21, shows an FVC increase (+633). My understanding of Pliant´s placebo clients shows the opposite.

Investors Betting on TOP Financial (TOP) Stock

It’s calculated by averaging the closing stock price over the previous 50 trading days. Pliant Therapeutics Inc 50-day moving average is $28.47. According to 12 analysts, the average rating for PLRX stock is “Strong Buy.” The 12-month stock price forecast is $44.92, which is an increase of 59.01% from the latest price.

Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Pliant Therapeutics Inc. shares soared 55% in their trading debut Wednesday, after the company’s initial public offering priced at $16 a share, the high end of its $14 to $16 range. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Also, the aftermath of the recent bank crisis and fears of a financial crunch are slowing the economy. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.

For the fiscal year ending December 2023, the company is expected to report a loss per share of $0.90. Likewise, analysts expect LOCL to report a loss per share of $0.68 for the next fiscal year . Furthermore, LOCL failed to surpass the consensus EPS and revenue estimates in three of four trailing quarters, which is disappointing. PLN is a drug currently in development by the company to treat patients suffering from Idiopathic Pulmonary Fibrosis. The current clinical trial was going over the safety and efficacy of treating these patients with the drug. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock.

Pliant Therapeutics Announces Pricing of Initial Public Offering – PR Newswire

Pliant Therapeutics Announces Pricing of Initial Public Offering.

Posted: Tue, 02 Jun 2020 07:00:00 GMT [source]

Pliant Therapeutics, Inc. was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in … KRBP has an F grade for Stability and Sentiment and a D for Growth and Momentum. It is ranked #376 among the 383 stocks in the Biotech industry. On March 10, 2023, KRBP announced that it would conduct a 1-for-30 reverse stock split of its common shares to comply with Nasdaq’s minimum bid price requirement.

Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), Innoviva (INVA) and Pliant Therapeutics (PLRX)

Pliant´s placebo clients seemed to decline at a rate around four times as fast as that of 1600 wholly untreated patients . If that understanding is right, then it is quite a worrying sign. Vicore Pharma has one IPF product and is at similar stage as Pliant. Vicore is trading at a 12 times lower valuation while having significantly stronger data than Pliant.


It focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, bexotegrast (PLN-74809), is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. News of the positive clinical trial results has PLRX stock seeing heavy trading on Monday. As of this writing, more than 37 million shares of the stock have changed hands.

Benzinga’s Top Ratings Upgrades, Downgrades For April 13, 2023

Both how to get bank guarantee in indias have incomparable results in comparison with Vicore. The USD 3.5 billion price tag represents a 35x multiple from the current share price. The technique has proven to be very useful for finding positive surprises. According to Pliant Therapeutics, results from the clinical trial were positive. This saw PLN succeed in meeting its primary and secondary endpoints in the clinical trial. That includes being well-tolerated over a 12-week period and showing a favorable pharmacokinetic profile.


Its net loss widened by 35.7% from the year-ago value to $34.73 million, resulting in a loss per share of $64.42. Moreover, as of December 31, 2022, the company’s total liabilities stood at $17.74 million, compared to $3.41 million as of December 31, 2021. 1.1% in the first quarter of 2023, falling short of estimates. This is a significant pullback from the 2.6% growth in the fourth quarter and a 3.2% increase in the third quarter of 2022. PLRX – The economic situation appears to be grim, with higher interest rates and the recent turmoil in the financial system causing sluggish growth in the first three months of this year.


The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. Pliant Therapeutics Inc 52 week low is $3.97 as of April 29, 2023. 52 week high is the highest price of a stock in the past 52 weeks, or one year. Pliant Therapeutics Inc 52 week high is $36.64 as of April 29, 2023.

Pliant´s sample of placebo clients is not really placebo – 80% of the placebo clients were treated on Standard of Care . “Be strategic when disclosing data” quote could be taken in several ways. In my view, it is quite a strange quote from a pharma CEO.

PLRX, +2.62% soared about 75% in premarket trading on Monday, the day after the company said a high dose of its experimental treatment for idiopathic pulmonary fibro… Shares of Pliant Therapeutics have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients. A reverse stock split is often seen as a red flag for investors, indicating that a company is struggling and trying to boost its stock price artificially. KRBP’s decision to do so to meet Nasdaq’s minimum bid price requirement suggests a struggle to maintain its listing status. LOCL’s loss from operations worsened by 111.4% year-over-year to $94.53 million for the fiscal year that ended December 31, 2022. Its adjusted EBITDA loss widened 67.4% from the prior year to $29.78 million.

We are short Pliant through long maturity deep out-of-the-money put options. The Pliant share price has been rising sharply despite rumours of another capital raise. In my view, there is a significant downside risk in the stock price.

Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA. EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases.

Harmony Biosciences down 15% after CEO leaves for Novavax … – Seeking Alpha

Harmony Biosciences down 15% after CEO leaves for Novavax ….

Posted: Mon, 09 Jan 2023 08:00:00 GMT [source]

PLRX’s weak fundamentals are reflected in its POWR Ratings. It has an overall F rating, equating to a Strong Sell in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree. PLRX has lost 19.7% over the past three months to close the last trading session at $28.00. Against this backdrop, it could be wise to steer clear of stocks PLRX, LOCL, and KRBP, with bleak fundamentals and poor outlooks. It is the first IPF drug that turns a deadly disease into a survivable one.

Research & Ratings Pliant Therapeutics Inc.(PLRX)

KRBP is an AI-driven allogeneic cell therapy company developing multi-indication therapies using Gamma Delta T cells to target solid tumors. Its product candidates include ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy targeting Isomesothelin, and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy targeting PD-L1. In terms of forward EV/Sales, the stock is trading at 4.90x, 180.9 higher than the industry average of 1.75x. LOCL’s forward Price/Sales of 1.52x is 31% higher than the industry average of 1.16x.

For the fourth quarter that ended December 31, 2022, PLRX’s revenue decreased 1.7% year-over-year to $1.97 million. Its loss from operations widened 52% from the year-ago value to $37.40 million. Moreover, its net loss and loss per share worsened by 42.9% and 5.9% year-over-year to $35.06 million and $0.72, respectively.

  • If the readouts continue to produce such strong results, Vicore will be taken over by a major.
  • It attempts to reflect the cash profit generated by a company’s operations.
  • The stock has plummeted 52.9% over the past six months and 76.9% over the past year to close its last trading session at $4.19.
  • Our calculations are based on comprehensive, delayed quotes.

The company did not provide any response to these points. The 12-week study shows a strong positive effect in weeks 0-4, which is followed by a decline in weeks 4-12. The decline is the same as with the placebo clients indicating that the drug works only in weeks 0-4 and then is the same as the placebo. Pliant Therapeutics is a USD 1.8 bn US based clinical-stage bio-pharmaceutical company developing new treatments for idiopathic pulmonary fibrosis . Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET.

  • The data looks positive at first glance as the placebo group looks to perform worse than treatment groups.
  • This is the company’s drug to treat Idiopathic Pulmonary Fibrosis.
  • KRBP’s decision to do so to meet Nasdaq’s minimum bid price requirement suggests a struggle to maintain its listing status.

EV/Sales, PLRX is trading at 412.53x, considerably higher than the industry average of 3.62x. The stock’s forward Price/Sales of 507.23x is significantly higher than the industry average of 4.05x. I/we have a beneficial short position in the shares of PLRX either through stock ownership, options, or other derivatives. This is the biggest and most important event for the IPF.

A valuation method that multiplies the of a company’s stock by the total number of outstanding shares. Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1…. KRBP’s loss from operations worsened by 20.9% year-over-year to $31.11 million for the fiscal year that ended December 31, 2022.

Kategoriler: Forex Trading